Standout Papers

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negativ... 1998 2026 2007 2016 4.4k
  1. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer (2004)
    Soonmyung Paik, Steven Shak et al. New England Journal of Medicine
  2. Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer (2002)
    Bernard Fisher, Stewart Anderson et al. New England Journal of Medicine
  3. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study (1998)
    Bernard Fisher, Joseph P. Costantino et al. JNCI Journal of the National Cancer Institute
  4. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer (2006)
    Soonmyung Paik, Gong Tang et al. Journal of Clinical Oncology
  5. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. (1998)
    Bernard Fisher, John Bryant et al. Journal of Clinical Oncology
  6. Five-Year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Segmental Mastectomy with or without Radiation in the Treatment of Breast Cancer (1985)
    Bernard Fisher, Madeline Bauer et al. New England Journal of Medicine
  7. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. (1997)
    Bernard Fisher, A Brown et al. Journal of Clinical Oncology
  8. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 (2008)
    Priya Rastogi, Stewart Anderson et al. Journal of Clinical Oncology
  9. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial (2010)
    David N. Krag, Stewart Anderson et al. The Lancet Oncology
  10. Eight-Year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Lumpectomy with or without Irradiation in the Treatment of Breast Cancer (1989)
    Carol Redmond, R Poisson et al. New England Journal of Medicine
  11. A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors (1989)
    B. Fisher, Joe Costantino et al. New England Journal of Medicine
  12. Reanalysis and Results after 12 Years of Follow-up in a Randomized Clinical Trial Comparing Total Mastectomy with Lumpectomy with or without Irradiation in the Treatment of Breast Cancer (1995)
    Bernard Fisher, Stewart Anderson et al. New England Journal of Medicine
  13. Ten-Year Results of a Randomized Clinical Trial Comparing Radical Mastectomy and Total Mastectomy with or without Radiation (1985)
    Bernard Fisher, Carol Redmond et al. New England Journal of Medicine
  14. Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18 (2001)
    Norman Wolmark, E. Mamounas et al. JNCI Monographs
  15. Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation (2002)
    Bernard Fisher, Jong‐Hyeon Jeong et al. New England Journal of Medicine
  16. Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study (2005)
    Bernard Fisher, Joseph P. Costantino et al. JNCI Journal of the National Cancer Institute
  17. The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27 (2003)
    Harry D. Bear, Stewart Anderson et al. Journal of Clinical Oncology
  18. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial (2007)
    David N. Krag, Stewart Anderson et al. The Lancet Oncology
  19. Postoperative Adjuvant Chemotherapy or Radiation Therapy for Rectal Cancer: Results From NSABP Protocol R-011 (1988)
    B. Fisher, Norman Wolmark et al. JNCI Journal of the National Cancer Institute
  20. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 (2006)
    Harry D. Bear, Stewart Anderson et al. Journal of Clinical Oncology
  21. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial (1999)
    James J. Dignam, Norman Wolmark et al. The Lancet
  22. Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03 (2009)
    Mark S. Roh, Linda H. Colangelo et al. Journal of Clinical Oncology
  23. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 (2014)
    Edith A. Perez, Edward H. Romond et al. Journal of Clinical Oncology
  24. Lumpectomy Compared with Lumpectomy and Radiation Therapy for the Treatment of Intraductal Breast Cancer (1993)
    Bernard Fisher, Joseph P. Costantino et al. New England Journal of Medicine
  25. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. (1998)
    Bernard Fisher, James J. Dignam et al. Journal of Clinical Oncology
  26. Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31 (2005)
    Elizabeth Tan-Chiu, Greg Yothers et al. Journal of Clinical Oncology
  27. L-Phenylalanine Mustard (L-PAM) in the Management of Primary Breast Cancer (1975)
    Bernard Fisher, Paul P. Carbone et al. New England Journal of Medicine
  28. Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31 (2011)
    Edith A. Perez, Edward H. Romond et al. Journal of Clinical Oncology
  29. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials (2005)
    Daniel J. Sargent, Harry S. Wieand et al. Journal of Clinical Oncology
  30. erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer (1998)
    Soonmyung Paik, John Bryant et al. JNCI Journal of the National Cancer Institute
  31. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. (1993)
    Norman Wolmark, Howard E. Rockette et al. Journal of Clinical Oncology
  32. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial (2018)
    Sibylle Loibl, Joyce O’Shaughnessy et al. The Lancet Oncology
  33. Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS (2011)
    Irene Wapnir, James J. Dignam et al. JNCI Journal of the National Cancer Institute
  34. Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses (2011)
    Greg Yothers, Michael J. O’Connell et al. Journal of Clinical Oncology
  35. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer (2016)
    Piero Dalerba, Debashis Sahoo et al. New England Journal of Medicine

Immediate Impact

6 from Science/Nature 121 standout
Sub-graph 1 of 12

Citing Papers

Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides
2023 StandoutNature
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
12 intermediate papers

Works of Norman Wolmark being referenced

Body Mass Index and Outcomes in Patients Who Receive Adjuvant Chemotherapy for Colon Cancer
2006
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
1998 Standout
and 6 more

Author Peers

Author Last Decade Papers Cites
Norman Wolmark 38425 39518 21375 528 67.3k
Bernard Fisher 23654 30424 16849 428 50.3k
Giuseppe Viale 28609 25471 12315 766 53.8k
Gabriel N. Hortobágyi 53018 36270 12422 1.1k 86.1k
Edwin R. Fisher 16785 21965 13561 330 36.7k
Kelly K. Hunt 17040 23711 15684 729 39.2k
Ian O. Ellis 27787 26157 13790 971 58.9k
Umberto Veronesi 12099 20996 13127 402 31.3k
Thomas A. Buchholz 14298 17123 8043 496 30.6k
Aman U. Buzdar 23340 20608 7678 505 38.6k
Eric P. Winer 35888 19716 5462 730 55.0k

All Works

Loading papers...

Rankless by CCL
2026